Sep. 11 at 9:05 PM
$LPTX Direct anti-GDF-15
Pfizer — ponsegromab (PF-06946860): Phase 2 in cancer cachexia; suppresses circulating GDF-15 and showed weight/PRO signals.
CatalYm — visugromab (CTL-002): Anti-GDF-15 for solid tumors/cachexia; moving toward pivotal work; FIH combo with anti-PD-1 reported responses.
AstraZeneca — AZD8853: Anti-GDF-15 in advanced solid tumors (Phase 1/2a FIH complete; safety OK, limited PD/efficacy so far).
AVEO Oncology — AV-380: Anti-GDF-15 IgG1 in cancer cachexia (ongoing Phase 1b dose-escalation).
Blocks GDF-15 activity via the receptor
NGM Biopharmaceuticals — NGM120: Anti-GFRAL antibody (b. Phase 2 in hyperemesis gravidarum underway; company says cachexia Phase 2 is planned.
Agonists of the GDF-15 pathway (primarily for weight loss) — active
Novo Nordisk — NNC0174-0833 : Studied for overweight/obesity (with GLP-1s). Multiple clinical trials completed/posted.
Notable discontinued GDF-15 pathway programs (for context)
Novartis — MBL949
Eli Lilly — LY3463251
